The Adoption of Nintedanib in Systemic Sclerosis: the SENSCIS Study

Overview

Journal Breathe (Sheff)

Specialty Pulmonary Medicine

Date 2020 Jul 16

PMID 32665787

Citations 5

Authors

Teresa Bruni

Francesco Varone

Affiliations

Soon will be listed here.

Abstract

http://bit.ly/2vfJRj7.

Citing Articles

Nintedanib and its combination with immunosuppressives in connective tissue disease-related interstitial lung diseases.

Tekgoz E, Colak S, Gunes E, Ocal N, Cinar M, Yilmaz S Ir J Med Sci. 2024; 194(1):391-397.

PMID: 39636517 DOI: 10.1007/s11845-024-03848-6.

Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.

Ilg M, Lapthorn A, Ralph D, Cellek S PLoS One. 2022; 17(12):e0277646.

PMID: 36508413 PMC: 9744312. DOI: 10.1371/journal.pone.0277646.

Macrophages as determinants and regulators of fibrosis in systemic sclerosis.

Al-Adwi Y, Westra J, Goor H, Burgess J, Denton C, Mulder D Rheumatology (Oxford). 2022; 62(2):535-545.

PMID: 35861385 PMC: 9891414. DOI: 10.1093/rheumatology/keac410.

Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis.

Papadimitriou T, van Caam A, van der Kraan P, Thurlings R Biomedicines. 2022; 10(2).

PMID: 35203525 PMC: 8869277. DOI: 10.3390/biomedicines10020316.

Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug.

Kafle S, Thapa Magar M, Patel P, Poudel A, Cancarevic I Cureus. 2021; 13(7):e16404.

PMID: 34414042 PMC: 8364831. DOI: 10.7759/cureus.16404.

References

Varone F, Sgalla G, Iovene B, Bruni T, Richeldi L . Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother. 2018; 19(2):167-175. DOI: 10.1080/14656566.2018.1425681. View

Wuyts W, Antoniou K, Borensztajn K, Costabel U, Cottin V, Crestani B . Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respir Med. 2014; 2(11):933-942. DOI: 10.1016/S2213-2600(14)70232-2. View

Flaherty K, Fell C, Huggins J, Nunes H, Sussman R, Valenzuela C . Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J. 2018; 52(2). PMC: 6092682. DOI: 10.1183/13993003.00230-2018. View

Tashkin D, Roth M, Clements P, Furst D, Khanna D, Kleerup E . Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016; 4(9):708-719. PMC: 5014629. DOI: 10.1016/S2213-2600(16)30152-7. View

Schoenfeld S, Castelino F . Interstitial lung disease in scleroderma. Rheum Dis Clin North Am. 2015; 41(2):237-48. PMC: 4385198. DOI: 10.1016/j.rdc.2014.12.005. View

Beretta L, Santaniello A, Lemos A, Masciocchi M, Scorza R . Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology (Oxford). 2006; 46(2):296-301. DOI: 10.1093/rheumatology/kel221. View

Vancheri C, Kreuter M, Richeldi L, Ryerson C, Valeyre D, Grutters J . Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit Care Med. 2017; 197(3):356-363. DOI: 10.1164/rccm.201706-1301OC. View

Distler O, Highland K, Gahlemann M, Azuma A, Fischer A, Mayes M . Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019; 380(26):2518-2528. DOI: 10.1056/NEJMoa1903076. View

Raghu G, Remy-Jardin M, Myers J, Richeldi L, Ryerson C, Lederer D . Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5):e44-e68. DOI: 10.1164/rccm.201807-1255ST. View

10.

Raghu G, Rochwerg B, Zhang Y, Garcia C, Azuma A, Behr J . An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015; 192(2):e3-19. DOI: 10.1164/rccm.201506-1063ST. View

11.

Cottin V, Brown K . Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019; 20(1):13. PMC: 6339436. DOI: 10.1186/s12931-019-0980-7. View

12.

Flaherty K, Wells A, Cottin V, Devaraj A, Walsh S, Inoue Y . Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18):1718-1727. DOI: 10.1056/NEJMoa1908681. View

13.

Tashkin D, Elashoff R, Clements P, Goldin J, Roth M, Furst D . Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354(25):2655-66. DOI: 10.1056/NEJMoa055120. View

14.

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

15.

Mendoza F, Keyes-Elstein L, Jimenez S . Systemic sclerosis disease modification clinical trials design: quo vadis?. Arthritis Care Res (Hoboken). 2012; 64(7):945-54. PMC: 3386473. DOI: 10.1002/acr.21667. View

16.

Behr J, Nathan S, Harari S, Wuyts W, Kirchgaessler K, Bengus M . Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design. Respir Med. 2018; 138:13-20. DOI: 10.1016/j.rmed.2018.03.019. View

17.

Herzog E, Mathur A, Tager A, Feghali-Bostwick C, Schneider F, Varga J . Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?. Arthritis Rheumatol. 2014; 66(8):1967-78. PMC: 4340472. DOI: 10.1002/art.38702. View

18.

Kolb M, Raghu G, Wells A, Behr J, Richeldi L, Schinzel B . Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018; 379(18):1722-1731. DOI: 10.1056/NEJMoa1811737. View

19.

Richeldi L, du Bois R, Raghu G, Azuma A, Brown K, Costabel U . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584. View

20.

Khanna D, Furst D, Clements P, Allanore Y, Baron M, Czirjak L . Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017; 2(1):11-18. PMC: 5431585. DOI: 10.5301/jsrd.5000231. View